Ronald Melki, CNRS delivers plenary and moderates roundtable at Synuclein meeting in Porto

2019-10-07T10:44:12+00:00September 10th, 2019|News|

On September 3, 2019, PD-MitoQUANT PI Dr Ronald Melki, Team Leader of the Protein misfolding and aggregation in neurodegenerative diseases group at CNRS delivered the keynote lecture at the 4-day SYNUCLEIN meeting.  Following on from the keynote talk, Ronald chaired a round table discussion titled: Alpha-synuclein aggregation: how does it happen? Participants at the table included Daniel Otzen, Ronald Melki and Hilal Lashuel. The 2019 meeting which took place in Ofir on the outskirts of Porto in Portugal was themed [...]

PD-MitoQUANT PIs at CNRS co-author review in the Journal of Neurochemistry

2019-10-07T10:30:57+00:00August 20th, 2019|News|

A review was recently published in the Journal of Neurochemistry which acknowledged PD-MitoQUANT research funding. "α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities" authored by a team consisting of Parvez Alam, Luc Bousset, Ronald Melki and Daniel E. Otzen appeared in the 29 June 2019 issue. Ronald and Luc are PD-MitoQUANT PIs from the Centre National de la Recherche Scientifique, the CNRS in France.  Download the open access paper here. Congratulations to all!  

Interview with PD-MitoQUANT PI Prof Dr Dino Di Monte, DZNE

2019-10-18T12:06:50+00:00June 20th, 2019|News|

A few questions were posed to PI Prof Dr Donato (Dino) DiMonte to gain his views on his work in Parkinson research and PD-MitoQUANT, in general. Dino is a senior researcher and leads the Neurodegeneration and Neuroprotection in Parkinson’s Disease Group at the German Center for Neurodegenerative Diseases (DZNE). Please describe your day to day work. It is difficult to describe a “typical” day of work. Most of the time, our working schedule involves specific tasks that vary from day [...]

Dr Ronald Melki, CNRS presents at World Parkinson Congress 2019

2019-10-18T11:36:39+00:00June 10th, 2019|News|

The 5th World Parkinson Congress (WPC) was held in Kyoto, Japan from June 4– 7, 2019. More than 3,000 people from more than 60 countries attended the meeting. At this meeting, Dr Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) and PD-MitoQUANT PI presented: "What is alpha-synuclein- The biology". Through Ronald's talk, PD-MitoQUANT funding was acknowledged. Dr Ronald Melki, CNRS at WPC 2019 The WPC 2019 hosted an international, interdisciplinary forum showcasing the most important [...]

Parkinson’s UK blog celebrates their involvement in new two IMI projects

2019-10-18T11:45:12+00:00May 30th, 2019|News|

Beckie Port "From innovation to better treatments" is the title of a blog post published on 27 May 2019 by Dr Beckie Port. Beckie is Research Communications Manager at PD-MitoQUANT partner Parkinson's UK. This blog entry announces partnerships with two pan-European, IMI-funded research projects: PD-MitoQUANT and Neuronet. In it, Beckie describes how these collaborative projects aim to accelerate research and deliver new treatments for Parkinson’s. Read the full blog post here.    

PD-MitoQUANT PI Ronald Melki, CNRS delivers plenary lecture at AAN 2019 meeting

2019-07-19T10:38:28+00:00May 20th, 2019|News|

PD-MitoQUANT PI Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) recently delivered the plenary lecture of the Frontiers in Neuroscience session of the American Academy of Neurology (AAN) annual meeting on May 8, 2019, in Philadelphia, USA. Through his talk, PD-MitoQUANT funding was acknowledged. More than 3000 were in attendance. The theme of the 71st AAN annual meeting was "Advancing Neurology, Advancing You". It was held May 4- 10th. The meeting offers unparalleled opportunities for professional and personal advancement [...]

Health Europa features news of PD-MitoQUANT

2019-07-03T08:34:16+00:00April 8th, 2019|News|

PD-MitoQUANT recently appeared in the news stream of HealthEuropa.eu. Read the story, “The Innovative Medicines Initiative, mitochondrial dysfunction and Parkinson’s". Read the story here. Health Europa highlights the latest trends and developments in health and healthcare from across Europe.  Their platform is a valuable news source to the health sector, allowing them to discuss research and innovation themes, health policy and new technologies. In addition, the website, HealthEuropa.eu has gained Google News approval. It features news, interviews and insightful commentary from leading figures, keeping readers [...]

PD-MitoQUANT makes headlines

2019-05-22T11:45:49+00:00March 19th, 2019|News|

Here is a list of international and national media coverage of the launch of PD-MitoQUANT: Bioengineer.org: Ireland to lead €7 million Parkinson's research project. Read the story here. SCIENMAG: Ireland to lead €7 million Parkinson's research project. Read the story here. Hospital Pharmacy Europe: Ireland to lead on €7 million Parkinson's research project. Read the story here. Bio Spectrum Asia: Ireland to lead €7 M Parkinson's research project. Read the story here. SiliconRepublic.com: Ireland’s RCSI to lead €7m Parkinson’s research project. Read the story here. Irish Mirror: €7m [...]

PD-MitoQUANT Official Press release- 12 March 2019

2019-03-20T22:04:50+00:00March 12th, 2019|News|

7 million euro awarded for Parkinson’s research through Innovative Medicines Initiative   New, more effective treatments are urgently needed for the more than one million people living with Parkinson’s in Europe today. While there are therapies available for the condition, they do not improve all symptoms, nor do they slow or prevent disease progression over time, and long-term treatment is associated with adverse side effects. PD-MitoQUANT (www.pdmitoquant.eu) is an Innovative Medicines Initiative (IMI - www.imi.europa.eu) research project that will improve [...]